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Abstract
Breast cancer is a complex disease, with heterogeneous clinical evolution. Several analyses have been performed to identify
the risk factors for breast cancer progression and the patients who respond best to a specific treatment. We aimed to
evaluate whether the hormone receptor expression, HER2 and MYC genes and their protein status, and KRAS codon 12
mutations may be prognostic or predictive biomarkers of breast cancer. Protein, gene and mutation status were
concomitantly evaluated in 116 breast tumors from women who underwent neoadjuvant chemotherapy with doxorubicin
plus cyclophosphamide. We observed that MYC expression was associated with luminal B and HER2 overexpression
phenotypes compared to luminal A (p,0.05). The presence of MYC duplication or polysomy 8, as well as KRAS mutation,
were also associated with the HER2 overexpression subtype (p,0.05). MYC expression and MYC gain were more frequently
observed in early-onset compared to late-onset tumors (p,0.05). KRAS mutation was a risk factor of grade 3 tumors
(p,0.05). A multivariate logistic regression demonstrated that MYC amplification defined as MYC/nucleus ratio of $2.5 was
a protective factor for chemotherapy resistance. On the other hand, age and grade 2 tumors were a risk factor. Additionally,
luminal B, HER2 overexpression, and triple-negative tumors presented increased odds of being resistant to chemotherapy
relative to luminal A tumors. Thus, breast tumors with KRAS codon 12 mutations seem to present a worse prognosis.
Additionally, MYC amplification may help in the identification of tumors that are sensitive to doxorubicin plus
cyclophosphamide treatment. If confirmed in a large set of samples, these markers may be useful for clinical stratification
and prognosis.
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Introduction
Several analyses have been performed to identify the risk factors
for breast cancer (BC) progression. The histological response to
preoperative chemotherapy is one of the most reliable predictors
for prognosis of BC patients. Many different chemotherapy
regimens have been applied in the preoperative setting. However,
the identification of patients who respond best to a specific
treatment is still critical to the appropriate management.
Some markers have been described as useful factors for
prognostic evaluation or predicting therapeutic response. Several
studies demonstrated that lack of estrogen (ER) and/or proges-
terone (PR) receptors predicts for chemosensitivity [1]. On the
other hand, it has been proposed that HER2 (c-erbB2) is a
predictor factor for either resistance or sensitivity to different types
of chemotherapeutic agents. However, the literature results are still
controversial, especially concerning the response to anthracyclines
[2].
ER, PR and HER2 had been used to classify tumors according
to luminal A (ER+/HER22), luminal B (ER+/HER2+), HER2
overexpression (ER2/HER2+), and triple-negative (ER2/PR2/
HER22) molecular subtypes. HER2 overexpression and triple-
negative are more aggressive and present poor prognosis than the
luminal subtypes [3,4]. Moreover, molecular phenotypes have
become increasingly valuable in guiding treatment decisions.
However, these markers remain imperfect tools and, therefore,
new prognostic and predictive factors are still required to optimize
treatments among BC patients [5].
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MYC acts as a downstream target of HER2-driven proliferative
signals in BC cells in vitro [6] and may be regulated by ER or PR
contributing to different cell phenotypes [7]. MYC plays a role in
the regulation of cell growth and proliferation, metabolism,
differentiation, apoptosis, and angiogenesis [8]. MYC amplification
and its protein overexpression have been found in about 15% and
40% of BC, respectively [9]. Due to the elevated frequency of
alteration, it has been advocated that MYC is involved in BC
development and progression [10].
Activation of HER2 induces activation of RAS, which enhances
the accumulation of MYC activity by stabilizing the MYC protein
[1,11]. In a transgenic mouse model, the synergistic effects of Myc
and the mutant Kras leads to breast tumor formation, mainte-
nance, and recurrence [12]. These data suggest that the KRAS
mutation may have a role in breast carcinogenesis.
In the present study, we evaluated the hormone receptor (HR)
expression, HER2 and MYC genes and their protein status, and
KRAS codon 12 mutations in BC from women who underwent
neoadjuvant chemotherapy, as well as their associations with
clinicopathological features and chemotherapy response.
Methods
Patients and tumor samples
During the period from 2005 to 2011, 116 females were selected
from a cohort of patients with locally advanced invasive ductal
carcinoma who underwent therapeutic surgery for a first incidence
of BC. All tumors were at stage III according to TNM staging
[13]. Cardiac problems, presence of distant metastasis, pregnancy
or lactation were exclusion criteria. The mean age of patients was
52612 years (range of 31–83).
All patients were treated at Ophir Loyola Hospital (Para´, Brazil)
and received Adriamycin (doxorubicin; 60 mg/m2) plus Cytoxan
(cyclophosphamide; 600 mg/m2) by intravenous every 21 days for
four cycles. The response to chemotherapy was based on the
change in the primary tumor size on pre- and post-therapy. The
tumor size was assessed by clinical palpation using a caliper.
Tumors were classified as sensitive to chemotherapy if complete
(macroscopic disappearance) or partial (at least a 50% reduction)
response was achieved. Tumors were defined as treatment-
resistant if no response (less than 50% reduction or less than
25% increase) or progression (at least a 25% increase or presence
of new lesions) was observed.
Tumors were obtained by incisional biopsy before neoadjuvant
chemotherapy. The tumor invasion and the nodal status were
determined according to TNM staging [13]. The histological
grade was assessed using the modified Scarff-Bloom-Richardson
system [14].
Tumors were classified as luminal A, luminal B, HER2
overexpression, and triple-negative subtypes based on the ER,
PR, and HER2 status [15]. We also classified data into tumors of
early-onset (patients with #40 years of age) and late-onset (.40
years) [16,17].
Tumors samples were formalin-fixed paraffin-embedded
(FFPE). Sections of FFPE tissue were stained with hematoxylin-
eosin for histological evaluation or used for immunohistochemical,
FISH and PCR analyses.
The study was approved by the ethics committee of the Federal
University of Para´, Brazil. Written informed consent with approval
of the ethics committee was obtained from all patients prior to
specimen collection.
Immunohistochemistry
Immunohistochemistry was performed with primary monoclo-
nal antibodies against ER (SAB4500810, Sigma, USA), PR
(HPA004751, Sigma, USA), HER2 (Clone CB11, Life Technol-
ogies, USA) or MYC (clone 289–19510, Life Technologies, USA).
Universal peroxidase-conjugated secondary antibody kit (Dako-
Cytomation, USA) was used for the detection system and 3,30-
diamino-benzidine/H2O2 (Dakocytomation, Denmark) was used
as the chromogen. Positive ER, PR or MYC expression was
defined as clear nuclear immunostaining in more than 10% of
tumor cells [18,19,20,21]. HER2 protein staining was scored as 0
(negative), 1+(weakly positive), 2+ (moderately positive) and 3+
(strongly positive) [2]. Double-blind analysis was performed on all
samples.
A breast tissue sample from a male with gynecomastia was used
as negative control. In addition, negative controls with primary
antibody replaced with Tris-buffered saline were run with the
patient slides.
Dual-color FISH
HER2 and MYC amplification was evaluated by dual-color
FISH assay using Dako ERBB2 FISH PharmDXTM Kit and
MYC/CEN-8 FISH Probe Mix (Dako A/S, Denmark), respec-
tively. FISH scoring was performed by counting fluorescence
signals in at least 60 tumor cells. Double-blind analysis was
performed on all samples.
For the detection of HER2 amplification, the ratio of HER2
signals to chromosome 17 (CEP17) signals was calculated
according to the established guidelines. Patients were stratified
depending on their HER2 gene status as: amplified if HER2/
CEP17 ratio .2.2; not amplified if HER2/CEP17,1.8; equivocal
if 1.8,HER2/CEP17,2.2 [2].
Since no established guideline was published, MYC amplifica-
tion was defined using different cutoffs as per previously-criteria: 1)
the ratio of MYC signals to chromosome 8 (CEP8) signals .2.2
[22,23] as applied for the detection of HER2 amplification; 2)
MYC/CEP8 ratio$1.3 (at least gene duplication) or MYC/CEP8
ratio,1.3 with polysomy 8 (3 or more copied of CEP8) [22,23];
3).5 MYC copies/nucleus (high MYC gain) [23]; 4)$2,5 MYC
copies/nucleus, which included low MYC gain [23].
Mutation analysis
DNA was purified using MagMAX
TM
FFPE DNA Isolation Kit
(Life Technologies, USA). KRAS codon 12 point mutation was
evaluated by PCR-RFLP as previously described [24]. PCR
products were digested with endonuclease BstOI. The digestion
products were electrophoresed on polyacrylamide gels with
SYBRH Safe DNA Gel Stain (Life Technologies, USA) and
visualized using blue light. The mutant-type (non-restricted PCR
products) were 189 bp, whereas the wild-type products were
160 bp (Figure 1). The PCR products of muted KRAS were
sequenced for confirmation of mutation using an ABI PrismH 377
DNA Sequencer (Life Technologies, USA).
A wild-type sample of peripheral blood lymphocytes from
normal healthy individual and a colorectal cancer sample with
codon 12 mutations were used as negative and positive controls,
respectively. The controls were included in all experiments. All
reactions were performed in duplicate.
Statistical analyses
Cohen’s kappa test (k) was used to evaluate the concordance
between the HER2 status by IHC and FISH. This rate was
calculated considering negative cases (scores 0 and 1+ and no
MYC and KRAS Alterations in Breast Cancer
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amplification), and positive cases (score 3+ and amplification).
Patients with equivocal IHC or FISH results were not considered
for this purpose [25]. Concordance was assessed by Fleiss’ equally
arbitrary guidelines, which characterize k values over 0.75 as
excellent, 0.40 to 0.75 as fair to good, and below 0.40 as poor [25].
In the remaining analyses, samples with HER2/CEP17.2.2
were classified as presenting HER2 amplification and with scores
of 2+ and 3+ as positive HER2 expression.
Logistic regression was used to evaluate the relationship
between protein immunoreactivity, gene amplification or muta-
tion, and clinicopathological features. IHC, FISH or PCR-RFLP
results, as well as molecular phenotype, were considered depen-
dent variables. Age was not added as a co-variable, since age did
not differ between groups (by Student’s T-test; data not shown).
A multivariate logistic regression in a forward stepwise approach
(condition method) was used to identify variables that may help to
predict chemotherapy resistance and to identify risk factors for
grade 3 tumors. Age was also added as a dependent variable in the
multivariate analyses.
In all analyses, p values less than 0.05 were considered
significant. Odds ratio (OR) with 95% confidence intervals are
shown.
Results
The protein and gene status and their relationships
For HER2, the percentage of concordant results between IHC
and FISH was equal to 93.9%, with a statistically significant k
value of 0.833. The 5 discordant cases were classified as score 1+
by IHC and showed gene amplification by FISH. In addition, 6/
32 of tumors classified as score 2+ presented HER2/CEP17 ration
$2.2 (Table 1).
Table 2 presents the IHC results and Table 3 the FISH results.
Figure 2 represents protein immunoreactivity by IHC and gene
amplification by FISH assay. No ER-positive case was found
without concomitant PR immunoreactivity. Therefore, tumors
with ER and PR immunoreactivity were renamed as HR-positive
cases for further analyses.
HER2 expression and its amplification were associated with HR
(p,0.001, OR: 0.162; 95% CI: 0.070–0.373; p = 0.001, OR:
0.173; 95% CI: 0.060–0.497, respectively) and MYC expression
(p,0.001, OR: 5.303, 95% CI: 2.255–12.473; p,0.001, OR:
58.333, 95% CI: 15.062–225.913, respectively) (Table 2 and 3).
MYC expression was also associated with HR (p= 0.023, OR:
0.379, 95% CI: 0.164–0.872) (Table 2). MYC gain was associated
with MYC (p,0.05, for all applied cutoffs), HR (p,0.05, for all
cutoffs) and HER2 expression (p,0.05, except for the cut point
#4), as well as with HER2 amplification (p,0.05, for all cutoffs)
(Table 3).
KRAS codon 12 mutation was observed in 9 (7.76%) tumors.
KRAS mutation was associated with HER2 (p = 0.033, OR: 4.565,
95% CI: 1.133–18.39) and MYC amplification (p = 0.043, OR:
4.850; 95% CI: 1.049–22.424, for cut point #1) (Table 4).
The impact of MYC and KRAS in the molecular phenotype
Taking in account the HR expression and HER2 amplification
to classify tumors by molecular phenotype, 49 (42.2%) of the
tumors were deemed luminal A, 5 (4.3%) were luminal B, 23
(19.8%) were HER2 overexpressed, and 39 (33.6%) were triple-
negative.
MYC expression was associated with luminal B and HER2
overexpression phenotypes (p = 0.008, OR: 24, 95% CI: 2.329–
247.368; p,0.001, OR: 63, 95% CI: 12.021–330.170; respec-
tively) compared to luminal A. The presence of MYC duplication
or polysomy 8 (cut point #2) was also associated with the HER2
overexpression subtype (p,0.001, OR: 49.867, 95% CI: 6.143–
404.814).
KRAS mutation was detected in 1/49 (2%) luminal A, 1/5 (20%)
luminal B, 4/23 (17.4%) HER2 overexpression and 3/39 (7.7%)
triple-negative tumors. KRAS mutation was associated with HER2
overexpression phenotype in relation to luminal A (p= 0.044, OR:
10.105, 95% CI: 1.06–96.336).
The impact of protein and gene status on
clinicopathological features
MYC expression and MYC gain were more frequently observed
in early-onset compared to late-onset tumors (p = 0.002, OR:
0.247, 95% CI: 0.100–0.610; p,0.05, for cutoffs #2 and #4;
respectively) (Table 2 and 3).
The expression of HR expression presented a protective effect
for grade 3 tumors (p = 0.014, OR: 0.23, 95% CI: 0.072–0.738)
Figure 1. Mutation analysis by PCR-RFLP of KRAS codon 12. 1
and 6: tumors with mutation. 2–5: tumors without mutation. L: size
marker.
doi:10.1371/journal.pone.0060576.g001
Table 1. HER2 protein and its gene status in the breast tumors.
IHC FISH Total
Not amplified Equivocal Amplified
1+ 60 (89.55%) 2 (2.99%) 5 (7.46%) 67 (57.76%)
2+ 23 (71.87%) 3 (9.38%) 6 (18.75%) 32 (27.59%)
3+ 0 (0%) 0 (0%) 17 (100%) 17 (14.65%)
Total 83 (71.55%) 5 (4.31%) 28 (24.14%) 116 (100%)
IHC: immunohistochemistry; FISH: fluorescence in situ hybridization.
doi:10.1371/journal.pone.0060576.t001
MYC and KRAS Alterations in Breast Cancer
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(Table 2). On the other hand, HER2 expression and KRAS
mutation was a risk factor for grade 3 tumors (p = 0.008, OR:
4.067, 95% CI: 1.433–11.537; p = 0.036, OR: 4.55; 95% CI:
1.102–18.788, respectively) (Table 2 and 4). Since HR and HER2
expression were associated with grade 3 tumors, logistic regression
was also performed using the molecular phenotype as dependent
variables. Women with HER2 overexpression and triple-negative
tumors (p = 0.027, OR: 5.412, 95% CI: 1.216–24.094; p = 0.017,
OR: 5.287, 95% CI: 1.342–20.836, respectively) had elevated risk
of being diagnosed with grade 3 tumors relative to those with
luminal A tumors.
The logistic regression model performed to verify if molecular
were together associated with the risk of grade 3 tumors showed
that the final model only included KRAS mutation.
The impact of protein and gene status on chemotherapy
response
The overall response rate of primary tumor to preoperative
chemotherapy was 43%. Among responsive patients, only 4 (8%)
patients died at the end of this study (minimum follow-up time of
over 12 months). These patients presented metastatic tumors
about 2 years after the treatment for primary cancer.
The expression of HR presented a protective effect for
treatment-resistance (p,0.001, OR: 0.042, 95% CI: 0.016–
0.113) (Table 1). On the other hand, HER2 expression and its
gene amplification were a risk factor for chemotherapy resistance
(p,0.001, OR: 8.610, 95% CI: 3.483–21.283; p= 0.001, OR:
6.571, 95% CI: 2.106–20.509, respectively) (Table 2 and 3).
Additionally, HER2 overexpression (p,0.001, OR: 46.67, 95%
CI: 9.229–235.97) and triple-negative (p,0.001, OR: 24.44, 95%
CI: 7.887–75.759) subtypes presented an increased risk of being
resistant to chemotherapy relative to luminal A.
MYC expression and its gene amplification were a risk factor for
chemotherapy resistance (p= 0.01, OR: 3.154, 95% CI: 1.318–
7.547; p,0.05, except when the cut point #4 was applied;
respectively) (Table 2 and 3).
We conducted a forward stepwise logistic regression model to
identify predictors of chemotherapy resistance, entering age, stage,
grade, molecular phenotype, KRAS mutation, MYC expression,
and the FISH results for detection of its amplification (including
the different cutoffs described above for MYC status) as dependent
Table 2. Clinicopathological features by protein expression status.
Factor (N) HR expression [N(%)] OR (95% CI) HER2 expression [N(%)] OR (95% CI) MYC expression [N(%)] OR (95% CI)
Negative Positive* Negative Positive* Negative Positive*
Age
#40 (27) 15 (12.93) 12 (10.34) 1.117
(0.470–2.655)
12 (10.34) 15 (12.93) 0.495
(0.207–1.182)
12 (10.34) 15 (12.93) 0.247
(0.100–0.610)**
.40 (89)* 47 (40.52) 42 (36.21) 55 (47.41) 34 (29.31) 68 (58.62) 21 (18.10)
Grade
1/2 (96) 46 (39.66) 50 (43.10) 0.230
(0.072–0.738)**
61 (52.59) 35 (30.17) 4.067
(1.433–11.537)**
67 (57.76) 29 (25.00) 1.244
(0.450–3.439)
3 (20)* 16 (13.79) 4 (3.45) 6 (5.17) 14 (12.07) 13 (11.21) 7 (6.03)
Tumor invasion
T1/T2 (9) 4 (3.45) 5 (4.31) 0.676
(0.172–2.656)
6 (5.17) 3 (2.59) 1.508
(0.358–6.352)
7 (6.03) 2 (1.72) 1.630
(0.322–8.264)
T3/T4 (107)* 58 (50) 49 (42.24) 61 (52.59) 46 (39.66) 73 (62.93) 34 (29.31)
Lymph node
metastasis
Absent (6) 6 (5.17) 0 (0) ,0.001 (0) 2 (1.72) 4 (3.45) 0.346
(0.061–1.971)
3 (2.59) 3 (2.59) 0.429
(0.082–2.235)
Present (110)* 56 (48.28) 54 (46.55) 65 (56.03) 45 (38.79) 77 (66.38) 33 (28.45)
Response to
therapy
Sensitive (50) 8 (6.90) 42 (36.21) 0.042
(0.016–0.113)**
42 (36.21) 8 (6.9) 8.610
(3.483–21.283)**
41 (35.34) 9 (7.76) 3.154
(1.318–7.547)**
Resistant (66)* 54 (46.55) 12 (10.34) 25 (21.55) 41 (35.34) 39 (33.62) 27 (23.28)
HR expression
Negative (62) – – – 24 (20.69) 38 (32.76) 0.162
(0.070–0.373)**
37 (31.90) 25 (21.55) 0.379
(0.164–0.872)**
Positive (54)* – – 43 (37.07) 11 (9.48) 43 (37.07) 11 (9.48)
HER2 expression
Negative (67) – – – – – – 56 (48.28) 11 (9.48) 5.303
(2.255–12.473)**
Positive (49)* – – – – 24 (20.69) 25 (21.55)
*Reference group for logistic regression analysis; ** Differentially expressed between groups, p,0.05. N: number of samples; OR: odds ratio; CI: confidence interval. HR:
hormone receptor.
doi:10.1371/journal.pone.0060576.t002
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variables. The OR was calculated considering the treatment-
resistant group in relation to chemotherapy sensitivity group. The
final model included MYC amplification defined as MYC/nucleus
ratio of $2.5 (cut point #4; p = 0.016, OR: 0.109, 95% CI:
0.018–0.664) as a protective factor. On the other hand, age
(p = 0.02, OR: 1.063, 95% CI: 1.01–1.12) was a risk factor.
Additionally, luminal B, HER2 overexpression, and triple-negative
tumors (p = 0.006, OR: 42.063, 95% CI: 2.956–598.51; p,0.001,
OR: 172.754, 95% CI: 15.754–1894.386; p,0.001, OR: 49.008,
95% CI: 8.789–273.268, respectively) presented increased odds of
being resistant to chemotherapy relative to luminal A tumors.
Moreover, grade 2 tumors presented an increased risk of being
resistant to treatment relative to grade 1 (p = 0.042, OR: 10.544,
95% CI: 1.087–102.252). However, grade 3 tumors did not
present an increased risk relative to grade 1 in this model.
Discussion
In this study, we evaluated ER and PR expression, HER2 and
MYC genes and their protein status, and KRAS mutations in the
same set of BC. First, we observed that 24% of tumors presented
HER2 amplification, corroborating a previous study (18–20%)
[26]. HER2 amplification is the primary mechanism of HER2
overexpression [27]. Although an excellent concordance between
IHC and FISH results was detected, 5 cases were scored as 1+ by
IHC and presented HER2 amplification. Since standardization of
IHC tests may be affected by preanalytical and analytical factors,
some groups have suggested the utilization of FISH results for
HER2 protein overexpression determination in BC [25]. There-
fore, we used only the FISH result for HER2 in the molecular
phenotype classification and, then, in the multivariate analyses.
Several definitions for MYC amplification have been used in BC
studies. However, these different definitions lead to inconsistent
results concerning the role of MYC in breast carcinogenesis. Here,
we applied different cutoffs to define MYC amplification as
described above, including the acceptance of low MYC gain with
or without polysomy 8. The frequency of MYC amplification
ranged from 11.2% (cut point #1) to 76.7% (cut point #4) in our
sample. Furthermore, MYC overexpression was detected in 31%
of BC. Although we found an association between MYC
amplification and its expression, as already described in previous
studies, our data confirm that mechanisms other than gene
amplification are involved in MYC overexpression in BC [9].
However, the assessments of MYC expression by IHC provide
variable results depending on the antibody, testing protocol, and
scoring system used [10], highlighting that FISH may be an
interesting tool in clinical practice due to its reproducibility.
Table 4. Clinicopathological features and protein expression
by KRAS mutation.
Factor (N) KRAS mutation [N(%)] OR (95% CI)
Absent Present*
Age
#40 (27) 23 (19.83) 4 (3.45) 0.342 (0.085–1.379)
.40 (89)* 84 (72.41) 5 (4.31)
Grade
1/2 (96) 91 (78.45) 5 (4.31) 4.550 (1.102–18.788)**
3 (20)* 16 (13.79) 4 (3.45)
Tumor invasion
T1/T2 (9) 8 (6.9) 1 (0.86) 0.646 (0.071–5.835)
T3/T4 (107)* 99 (85.34) 8 (6.9)
Lymph node metastasis
Absent (6) 5 (4.31) 1 (0.86) 0.392 (0.041–3.775)
Present (110)* 102 (87.93) 8 (6.9)
Response to therapy
Sensitive (50) 48 (41.38) 2 (1.72) 2.847 (0.565–14.345)
Resistant (66)* 59 (50.86) 7 (6.03)
HR expression
Negative (62) 55 (47.41) 7 (6.03) 0.302 (0.060–1.522)
Positive (54)* 52 (44.83) 2 (1.72)
HER2 expression
Negative (107) 63 (54.31) 4 (3.45) 1.790 (0.455–7.043)
Positive (9)* 44 (37.93) 5 (4.31)
MYC expression
Negative (80) 76 (65.52) 4 (3.45) 3.065 (0.771–12.176)
Positive (36)* 31 (26.72) 5 (4.31)
HER2 amplification
Negative (88) 84 (72.41) 4 (3.45) 4.565 (1.133–18,390)**
Positive (28)* 23 (19.83) 5 (4.31)
MYC amplification
MYC/CEP8#2.2 (103) 97 (83.62) 6 (5.17) 4.850 (1.049–22.424)**
MYC/CEP8.2.2 (13)* 10 (8.62) 3 (2.59)
*Reference group for logistic regression analysis; ** Differentially expressed
between groups, p,0.05. N: number of samples; OR: odds ratio; CI: confidence
interval. HR: hormone receptor; CEP8: chromosome 8 signals.
doi:10.1371/journal.pone.0060576.t004
Figure 2. IHC and FISH analysis in breast tumors. a) Progesterone
immunoreactivity (400x); b) Estrogen immunoreactivity (100x); c) HER2
immunoreactivity, score 3+ (400x); d) Interphase nuclei presenting two or
more signals for chromosome 17 centromere (green) and HER2 (red)
(1000x); e) MYC immunoreactivity (400x); f) Interphase nuclei presenting
two or more chromosome 8 centromere (green) and MYC signals (red)
(1000x).
doi:10.1371/journal.pone.0060576.g002
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We observed that MYC amplification and expression were more
frequent in BC without ER or PR expression, corroborating
previous studies [23]. However, some investigations did not find
such inverse correlation or even show the opposite correlation (see
review [28]). Although literature findings are inconsistent regard-
ing associations between MYC amplification and clinicopatholog-
ical parameters (in part, probably due to the lack of a unique cutoff
for MYC amplification definition), a meta-analysis demonstrated
that the correlation of MYC amplification with PR negativity was
the only statistically significant association [29].
Here, we detected an association between MYC and HER2, as
previously reported [30,31]. As expected, we also observed an
association between MYC expression or its amplification with
luminal B or HER2 overexpression in relation to luminal A,
confirming the results for HER2 and HR described above. These
findings suggest that MYC may be involved in subtype-specific
pathways.
MYC expression and gain were more frequently observed in
early-onset compared to late-onset BC. To our knowledge, this is
the first study to report this association in human primary BC. The
exact mechanisms by which MYC may be involved in early-onset
BC needs to be elucidated. However, MYC amplification seems to
be associated to BRCA1 inactivation in a group of hereditary and
sporadic BC [32]. BRCA1 inactivation is usually predisposed to
early-onset tumors, with a distinct phenotype characterized by
high tumor grade, aneuploidy, high proliferation rate, and ER-
negativity [32]. The investigation of MYC targets is still necessary
to better understand the heterogeneity of BC.
MYC amplification, as well as HER2 amplification, was
associated with KRAS codon 12 mutation. In BC cells, KRAS
may be activated by HER2 [1], enhancing the accumulation of
MYC activity [11], which may lead to chromosomal instability
[33] and contribute to MYC amplification. KRAS mutation was
detected in 7.76% of the tumors, corroborating a previous study
which reported that 5% of BC presented some KRAS mutation
[34]. More than one case of HER2 overexpression and triple-
negative subtypes presented KRAS mutation. However, previous
studies did not find any KRAS mutation in triple-negative tumors,
probably due to its low frequency [35,36]. Thus, an increased
number of tumors are essential to provide evidence of the role of
KRAS in human breast carcinogenesis.
In our population, HER2 overexpression and triple-negative
were more frequently grade 3 tumors, which is in agreement with
the more aggressive phenotype of these tumors [3,4]. Additionally,
we observed that the KRAS mutation was the main predictive
factor for grade 3 tumors. Due to its small frequency, further
investigations are still necessary to evaluate whether a KRAS codon
12 mutation may predict a worse prognosis in BC patients.
Concerning the response to chemotherapy, we observed that
HR predicts chemosensitivity, as previously reported [1]. On the
other hand, HER2 amplification or expression predicts resistance
to anthracyclines in our sample, highlighting that this group of
patients may be suitable for treatment with the monoclonal
antibody trastuzumab [37].
Furthermore, MYC expression and amplification (except when
accepting low MYC gain) was a risk factor for chemoresistance by
univariate logistic regression. However, in the multivariate analysis
to identify predictors of resistance to doxorubicin plus cyclophos-
phamide drugs, we observed that MYC amplification (including
low ratio of MYC gain) was a predictor of chemosensibility when
adjusted by grade, age, and the molecular phenotyping. This
finding is probably due to the significant association of MYC with
both HR (good prognosis) and HER2 (worse prognosis).
MYC may have a dual function in cancer cells, i.e. it can
promote cell proliferation or induces apoptosis [8] depending on
molecular background and tumor microenvironment. Since
rapidly proliferating cells are generally more sensitive to chemo-
therapy, it has been suggested that MYC may sensitive BC cells to
apoptosis [38]. Previous in vitro studies demonstrated greater
sensitivity of BC cells with MYC amplification to paclitaxel and to
doxorubicin compared to those without this amplification
[39,40,41]. To our knowledge, few studies evaluated the possible
role of MYC as a predictor for chemotherapy response in humans.
Yasojima et al. reported that MYC was associated with the
response to neoadjuvant chemotherapy comprising paclitaxel
followed by 5-FU/epirubicin/cyclophosphamide by univariate
analysis. However, the multivariate analysis failed to show such
association [38]. Without performing a multivariate analysis,
Todorovic-Rakovic et al. suggested that patients with MYC
amplification treated with chemotherapy (cyclophosphamide,
methotrexate and 5-fluorouracil or 5-fluorouracil, adriablastin
and cyclophosphamide) had clinical benefits in contrast to patients
without amplification [7]. Furthermore, Perez et al. reported that
tumors with MYC gain or polysomy 8 appeared to derive more
benefits from trastuzumab than tumors without these alterations.
The author also reported that patients with MYC/HER2
coamplification benefited significantly more from trastuzumab
than patients with only HER2 amplification [23]. Our results and
those from the literature suggest that MYC amplification may be
used as a predictor factor for chemosensibility and treatment
determination. However, it is important to evaluate several
markers concomitantly to try to determine a statistical model to
identify patients who would best respond to a treatment.
As a result of the increased number of chemotherapy regimens
that have been applied in the preoperative setting, it is becoming
increasingly important to identify patients who carry a particularly
high risk for being unresponsive for a specific treatment. To our
knowledge, this is the first study to evaluate the possible prognostic
and predictive significance of MYC and KRAS alterations
concomitantly with HR and HER2 status, in BC patients treated
with neoadjuvant doxorubicin plus cyclophosphamide drugs. We
observed an association among the molecular markers investigat-
ed. BC with KRAS codon 12 mutations seem to present a worse
prognosis. Additionally, MYC amplification may help in the
identification of tumors that are sensitive to doxorubicin plus
cyclophosphamide. If confirmed in a large set of samples, these
markers may be useful for clinical stratification and prognosis.
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